Loading...
12 tixagevimab/cilgavimab COVID-19 controlled studies, 5 RCTs
-29% improvement
for early treatment, RR
1.29
[0.42-3.95]
https://c19early.org/tcmeta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
TACKLE
Montgom.. (DB RCT)
0%
1.00 [0.32-3.07]
death
6/452
6/451
Improvement, RR [CI]
Treatment
Control
TACKLE
Montgom.. (DB RCT)
50%
0.50 [0.29-0.86]
severe case
18/407
37/415
TACKLE
Montgom.. (DB RCT)
57%
0.43 [0.25-0.75]
hosp.
17/413
40/421
Lombardi
-368%
4.68 [0.31-71.6]
death
1/19
1/89
OT1
Lombardi
33%
0.67 [0.09-5.13]
hosp.
1/19
7/89
OT1
Lombardi
-24%
1.24 [0.90-1.70]
viral+
14/19
53/89
OT1
ACTIV-3-TICO
Holland (DB RCT)
30%
0.70 [0.50-0.97]
death
61/710
86/707
ACTIV-3-TICO
Holland (DB RCT)
7%
0.93 [0.83-1.03]
no recov.
710 (n)
707 (n)
FDA (DB RCT)
40%
0.60 [0.35-1.03]
symp. case
28/749
23/372
FDA (DB RCT)
33%
0.67 [0.36-1.24]
symp. case
23/749
17/372
PROVENT
Levin (DB RCT)
86%
0.14 [0.01-2.98]
death
0/3,441
2/1,731
PROVENT
Levin (DB RCT)
82%
0.18 [0.09-0.35]
symp. case
11/3,441
31/1,731
PROVENT
Levin (DB RCT)
76%
0.24 [0.10-0.55]
symp. case
8/3,441
17/1,731
Young-Xu (PSM)
64%
0.36 [0.18-0.73]
death
1,733 (n)
6,354 (n)
Immunocompromised
Young-Xu (PSM)
69%
0.31 [0.18-0.53]
cases/death/hosp.
17/1,733
206/6,354
Immunocompromised
Young-Xu (PSM)
87%
0.13 [0.02-0.99]
hosp.
1,733 (n)
6,354 (n)
Immunocompromised
Young-Xu (PSM)
66%
0.34 [0.13-0.87]
cases
1,733 (n)
6,354 (n)
Immunocompromised
Kertes
92%
0.08 [0.01-0.54]
death/hosp.
1/825
63/4,299
Immunocompromised
Kertes
47%
0.53 [0.32-0.85]
cases
29/825
308/4,299
Immunocompromised
Najjar-Debbiny
59%
0.41 [0.19-0.89]
hosp.
72/703
377/2,812
Najjar-Debbiny
25%
0.75 [0.58-0.96]
cases
72/703
377/2,812
Levin (DB RCT)
75%
0.25 [0.01-6.10]
severe case
0/749
1/372
Levin (DB RCT)
42%
0.58 [0.34-1.00]
symp. case
27/749
23/372
Levin (DB RCT)
33%
0.67 [0.36-1.24]
symp. case
23/749
17/372
Sindu (PSM)
-1%
1.01 [0.14-7.21]
death
2/17
2/17
Sindu (PSM)
-96%
1.96 [0.18-21.6]
ventilation
n/a
n/a
Sindu (PSM)
-210%
3.10 [0.32-29.8]
ICU
n/a
n/a
Sindu (PSM)
53%
0.47 [0.16-1.40]
hosp.
n/a
n/a
Sindu
29%
0.71 [0.46-1.11]
symp. case
24/203
57/343
Din
19%
0.81 [0.32-2.04]
hosp.
5/23
11/41
Desai
12%
0.88 [0.33-2.35]
hosp.
391 (n)
391 (n)
Desai
-35%
1.35 [0.87-2.10]
cases
391 (n)
391 (n)
Tixagevimab/cilgavimab COVID-19 outcomes
c19 early .org
October 2023
1 OT: comparison with other treatment
Favors tixagevimab/ci..
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit